Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6526
    +0.0026 (+0.40%)
     

  • OIL

    82.78
    -0.03 (-0.04%)
     

  • GOLD

    2,337.90
    -0.50 (-0.02%)
     

  • Bitcoin AUD

    97,465.56
    -4,028.91 (-3.97%)
     

  • CMC Crypto 200

    1,361.57
    -21.00 (-1.52%)
     

  • AUD/EUR

    0.6083
    +0.0012 (+0.20%)
     

  • AUD/NZD

    1.0953
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,096.98
    +56.60 (+0.70%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,985.74
    -102.96 (-0.57%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Why AbbVie and Amgen Are Moving Lower Today

George Budwell, The Motley Fool
·2-min read
Why AbbVie and Amgen Are Moving Lower Today

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry.

Continue reading